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AbstrAct: 
Aim and clinical rationale for study. In Poland, it is widely believed that the outlook for ischaemic stroke patients is gradually 
improving due to the development of a network of stroke wards and other dedicated hospital units throughout the country. 
However, a study by Shah et al., reporting a significant increase in mortality from ischaemic stroke in several European countries 
including Poland, contradicts this belief. Therefore, the aim of this study was to determine the risk factors for death in patients 
with recent ischaemic stroke among a population of patients from Western Pomerania, a region in north-western Poland. 
Materials and methods. This retrospective study involved 2,374 patients with recent ischaemic stroke. Mortality was defined 
as death within 30 days of admission to hospital. Patients who died in hospital during this period were defined as deceased, 
while those who survived beyond this time were classified as alive. 
results. We found that compared to ischaemic stroke patients who survived, the group of ischaemic stroke patients 
who died included a higher number of patients who smoked cigarettes (OR = 6.08 in univariable model; OR = 6.22 in adjusted 
model), had hypertension (OR = 2.57; OR = 1.85), had a history of previous stroke (OR = 2.63; OR = 2.14), had coronary heart 
disease (OR = 1.78; OR=1.36), and were older (OR = 1.06; OR = 1.05). For all these factors, p-value was lower than 0.001. Females 
had a higher risk of death (OR = 1.48, p < 0.001; OR = 1.35, p = 0.01). For dyslipidemia, only univariable model was statistically 
significant (OR = 1.38, p < 0.001).
conclusion and clinical implications. Older age, female sex, dyslipidemia, hypertension, coronary heart disease, and smok-
ing are not only recognised risk factors for ischaemic stroke, but also risk factors associated with an unfavourable prognosis 
following stroke.
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Introduction
Ischaemic stroke (IS) is one of the most common causes 
of death and long-term disability. Due to the need for patients 
to undergo long-term rehabilitation and care, it is also one of 
the most expensive diseases to treat [1]. Over the last decade, 
there has been a marked decline in mortality resulting from IS 
throughout much of Europe, reflecting positive trends in the 
prevention of cardiovascular disease as a whole. These trends 
result from early implementation of primary prevention stra-
tegies and improved treatment and care, leading to a reduction 
in mortality among IS patients. Despite these changes, stroke 
remains the second leading cause of death in Europe after 
ischaemic heart disease, responsible for 9% of deaths in men 
and 13% in women [2].  
Clinical rationale for this study
In Poland, it is widely believed that the outlook for IS 
patients is gradually improving due to the development of 
a network of stroke wards and other dedicated hospital units 
throughout the country, which is confirmed by the GBD 
2016 Stroke Collaborators study [3]. However, a study by Shah 
et al., reporting a significant increase in mortality from IS in 
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both men and women in several European countries including 
Poland, contradicts this belief [4]. Therefore, the aim of this 
study was to determine the risk factors for death in patients 
with recent IS among a population of patients from Western 
Pomerania, a region in north-western Poland.
Materials and methods
This retrospective study involved 2,374 patients with recent 
IS, hospitalised at the Department of Neurology, Pomeranian 
Medical University in Szczecin between December 2014 and 
January 2019. A standardised data sheet was used to record 
gender, age, presence of hypertension, diabetes, dyslipidemia, 
history of ischaemic stroke, coronary heart disease, significant 
stenosis of the internal carotid artery, and tobacco smoking. 
Mortality was defined as death within 30 days of admission 
to hospital. Patients who died in hospital during this period 
were defined as ‘deceased’, while those who survived beyond 
this time were classified as ‘alive’. In our study, 1,679 patients 
(71%) survived this period, while 695 died (29%).
IS was defined as sudden onset of a focal neurological 
deficit, as determined by brain computed tomography and/
or magnetic resonance imaging. Diabetes mellitus was de-
fined by elevated fasting blood glucose greater than 126 mg/
dl in at least two tests or a fasting blood glucose greater than 
200 mg/dl at any time during the day before a stroke episode 
[5]. Dyslipidemia was defined as the combination of serum 
cholesterol concentration > 190 mg/dl, low-density cholesterol 
> 115 mg/dl, serum triglyceride concentration > 150 mg/
dl, and high-density cholesterol < 40mg/dl in males and
< 45mg/dl in females before a stroke episode [6]. Hyperten-
sion was diagnosed when blood pressure was greater than
140/90 mmHg in repeated tests before a stroke episode [7].
Coronary heart disease was determined by a previous history 
of angina pectoris, myocardial infarction or coronary artery
disease without infarction. Smokers were defined as people
who had smoked one or more cigarettes in their lifetime.
Previous stroke was considered to be present if the medical
charts included a stroke diagnosis. Based on examination USG 
or angio-CT or angio-MR, significant stenosis of the internal 
carotid artery was defined as stenosis of 70% or higher [8, 9]. 
Due to the fact that the above-mentioned risk factors are also 
recognised risk factors for atrial fibrillation, atrial fibrillation 
was not taken into further analysis. The Pomeranian Medical 
University Ethics Committee approved the study protocol
(KB-0012/178/07/19).
Statistics
To compare the characteristics of IS in patients who 
survived to those of the deceased, the Mann-Whitney Test 
(quantitative data) and the Fisher Exact Test (qualitative data) 
were used. In addition, univariable and multivariable logistic 
regression models were calculated for assessing the odds ratios 
of chosen risk factors of death incidence among IS patients. 
Statistical significance was set at p<0.01. All statistical analyses 
were performed using ‘R’ programming environment.
Results
Analysis of risk factors for death in ischaemic 
stroke patients
Cigarette smoking, hypertension, older age, female gender, 
dyslipidemia, coronary heart disease, and history of ischaemic 
stroke were more common in IS patients who died than in sur-
viving IS patients. A case comparison is presented in Table 1. 
Compared to ischaemic stroke patients who survived, 
the group of ischaemic stroke patients who died included 
a higher number who smoked cigarettes (OR = 6.08 in univari-
able model; OR = 6.22 in adjusted model), had hypertension 
(OR = 2.57; OR = 1.85), had a history of a previous stroke 
(OR = 2.63; OR = 2.14), had coronary heart disease (OR = 1.78; 
OR = 1.36), and were older (OR = 1.06; OR = 1.05). For all 
these factors, p-value was lower than 0.001. Also, females 
had a higher risk of death (OR = 1.48, p < 0.001; OR = 1.35, 
p = 0.01). For dyslipidemia, only univariable model was sta-
tistically significant (OR = 1.38, p < 0.001) (Tab. 2).
Discussion
Hypertension is not only one of the most frequent causes 
of stroke, but also increases the risk of morbidity and mortality 
from cardiovascular causes [10]. Treatment of hypertension 
reduces the risk of general mortality, and the reduction of risk 
depends on the degree of pressure reduction. Thus, lowering 
high blood pressure has been proposed as a major factor for 
the reduction in stroke death rates during the 21st century 
[11]. In a meta-analysis involving one million adult patients, 
the researchers found that between the ages of 40–69 years, 
each incremental rise of 20 mmHg systolic blood pressure and 
10 mmHg diastolic blood pressure, beginning with systolic 
blood pressure of 115mmHg and diastolic blood pressure of 
75mmHg, was associated with a two-fold increase in death 
rates from stroke [12]. Other clinical analysis have demon-
strated that control of isolated systolic blood pressure reduces 
total and stroke mortality [13, 14]. Reductions of 4.7 mmHg 
blood pressure reduced stroke mortality by 17.6% [15]. Our 
study confirms that arterial hypertension in ischaemic stroke 
patients is a prognostic factor, as it increases the risk of death 
by a factor of 2.5.
The impact of cigarette smoking on stroke risk and morta-
lity is also well established [16]. Estimates of the risk of stroke 
related to smoking vs. non-smoking vary according to epide-
miological studies and stroke type. However, there is a correla-
tion between the number of cigarettes smoked and the risk of 
ischaemic stroke. Likewise, cessation of smoking reduces the 
risk of stroke [17]. In spite of this, there are discrepancies in 
the research as to whether smoking can serve as a prognostic 
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n = 695 
p value
Age Mean/Median/SD
68.15/67.0/11.65 75.5/78.0/10.79 < 0.001
sex
F 873 (36.8%) 428 (18.0%) < 0.001
M 806 (34.0%) 267 (11.2%)
Diabetes mellitus
no 1146 (48.3%) 458 (19.3%) 0.27
yes 533 (22.5%) 237 (10.0%)
Dyslipidemia
no 1095 (46.1%) 400 (16.8%) < 0.001
yes 584 (24.6%) 295 (12.4%)
Hypertension
no 490 (20.6%) 96 (4.0%) < 0.001
yes 1189 (50.1%) 599 (25.2%)
IcA significant stenosis/occlusion
no 1425 (60.0%) 605 (25.5%) 0.18
yes 254 (10.7%) 90 (3.8%)
coronary heart disease
no 944 (39.8%) 291 (12.3%) < 0.001
yes 735 (31.0%) 404 (17.0%)
smoking
no 1,356 (57.1%) 284 (12.0%) < 0.001
yes 323 (13.6%) 411 (17.3%)
Previous stroke
no 1,341 (56.5%) 418 (17.6%) < 0.001
yes 338 (14.2%) 277 (11.7%)
factor. In our analysis, cigarette smoking was associated with 
a six-fold increase in the risk of death in ischaemic stroke 
patients. In a study conducted by Kuller et al., among the 
361,662 men analysed, the risk of mortality from ischaemic 
stroke among smokers was 2.5 times greater than among those 
who had never smoked [18]. In another study, the risk of stro-
ke mortality in current smokers compared to never-smokers 
was 1.7 times greater in men and 2.2 times greater in women 
[19]. These observations seem to be confirmed by Towfighi 
et al., who in their work showed that among ischaemic stroke 
patients, abstinence from smoking was associated with lower 
overall mortality [20]. 
At least 25% of ischaemic stroke patients experience 
a recurrent stroke within five years after the first stroke. Very 
often, recurrent strokes are characterised by poor prognosis 
and end in death within the first month after its occurrence 
in 25% of patients [21]. The risk of recurrence is the highest 
in the first six months after the first vascular episode. Within 
10 years, it is six times higher than the risk of first stroke in 
the general population of the same age and sex [22]. Recurrent 
strokes are accompanied by an increased risk of disability and 
are associated with higher costs compared to the first vascular 
episode. Numerous epidemiological studies have shown that 
early mortality is more often associated with recurrent stroke, 
whereas later mortality is usually associated with cardiovascu-
lar causes [23–26]. In our analysis, recurrent ischaemic stroke 
was associated with a doubled risk of death.
The relationship between ischaemic heart disease and 
increased mortality in cerebral ischaemic stroke patients has 
been demonstrated in many studies [27, 28]. In our study, 
a history of ischaemic heart disease in patients with cerebral 
ischaemic stroke was associated with a 1.7 times higher risk of 
death compared to patients without ischaemic heart disease.
In most age groups, the incidence rate of stroke is higher in 
men, although after the age of 85 it is higher in women. As the 
population ages, the proportion of stroke incidence between 
men and women also shifts. It is predicted that by 2050, 60% 
of stroke patients will be women. Most researchers agree that 
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table 2. Analysis of risk factors of death in patients with ischaemic stroke (univariable and multivariable logistic regression models)
Factors Univariable Logistic regression Models Multivariable Logistic regression Model *
Or cI P –value Or cI P –value
Age
1.06 1.05–1.07 < 0.001 1.05 1.04–1.06 < 0.001
Hypertension
yes 2.57 2.03–3.28 < 0.001 1.85 1.42–2.44 < 0.001
no 1.0 – – 1.0 – –
smoking
yes 6.08 5.01–7.38 < 0.001 6.22 5.02–7.73 < 0.001
no 1.0 – – 1.0 – –
Previous stroke
yes 2.63 2.17–3.19 < 0.001 2.14 1.71–2.68 < 0.001
no 1.0 – – 1.0 – –
Dyslipidemia
yes 1.38 1.15–1.66 < 0.001 0.85 0.69–1.06 0.15
no 1.0 – – 1.0 – –
IcA significant stenosis/occlusion
yes 0.83 0.64–1.08 0.17 0.73 0.54–0.98 0.04
no 1.0 – – 1.0 – –
sex
M 1.0 – – 1.0 – –
F 1.48 1.24–1.77 < 0.001 1.35 1.09–1.68 0.01
Diabetes mellitus
yes 1.11 0.92–1.34 0.26 0.96 0.77–1.19 0.7
no 1.0 – – 1.0 – –
coronary heart disease
yes 1.78 1.49–2.13 < 0.001 1.36 1.1–1.68 < 0.001
no 1.0 – – 1.0 – –
Status = 1 — deceased, status = 0 — alive 
*Fully adjusted model; Independent variables: Age; Hypertension (yes/no); Smoking (yes/no); Previous Stroke (yes/no); Dyslipidemia (yes/no); ICA significant stenosis/occlusion (yes/no); Sex (M/F); Diabetes 
mellitus (yes/no); Coronary heart disease (yes/no)
disability and mortality rates are higher in women due to their 
older age at the time of stroke. The increased mortality of fe-
male patients is largely due to the initial differences between 
men and women, i.e. the distribution of coexisting diseases, the 
severity of stroke, and age. In this study, both female sex and 
older age were unfavourable factors in determining prognosis. 
Many studies have also shown that older age has a negative 
impact on stroke morbidity, short and long-term outcomes, 
and mortality [29–31]. 
The relationship between dyslipidemia and ischaemic 
stroke is a complex issue in light of current research. In 
some studies, dyslipidemia has been associated with a worse 
prognosis, while other reports refute this [32–37]. Also, in 
our study, univariable analyses showed that the concurrence 
of dyslipidemia in ischaemic stroke patients was associated 
with higher mortality; however, this was not confirmed by 
multivariable analyses, which probably results from hetero-
geneity of strokes.
It is worth mentioning that our study had several limi-
tations. This was a single centre retrospective study, with 
a limited number of IS patients. We selected only the most 
common risk factors of IS. Further prospective studies with 
a larger sample size are needed.
Clinical implications/future directions
Older age, female sex, dyslipidemia, hypertension, coro-
nary heart disease, and smoking are not only recognised risk 
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factors for ischaemic stroke, but also risk factors associated 
with an unfavourable prognosis following stroke. Our research 
indicates the need for particularly thorough and systematic 
care of patients who exhibit the aforementioned factors. The 
results indicate the significance of lifestyle modification, inclu-
ding cessation of smoking, dietary adjustment, and, if possible, 
increased physical activity among this group of patients. 
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